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It has been proposed that D-amino acid oxidase (DAO) plays an essential role in
degrading D-serine, an endogenous coagonist of N-methyl-D-aspartate (NMDA) glutamate
receptors. DAO shows genetic association with amyotrophic lateral sclerosis (ALS) and
schizophrenia, in whose pathophysiology aberrant metabolism of D-serine is implicated.
Although the pathology of both essentially involves the forebrain, in rodents, enzymatic
activity of DAO is hindbrain-shifted and absent in the region. Here, we show activity-based
distribution of DAO in the central nervous system (CNS) of humans compared with that
of mice. DAO activity in humans was generally higher than that in mice. In the human
forebrain, DAO activity was distributed in the subcortical white matter and the posterior
limb of internal capsule, while it was almost undetectable in those areas in mice. In
the lower brain centers, DAO activity was detected in the gray and white matters in a
coordinated fashion in both humans and mice. In humans, DAO activity was prominent
along the corticospinal tract, rubrospinal tract, nigrostriatal system, ponto-/olivo-cerebellar
fibers, and in the anterolateral system. In contrast, in mice, the reticulospinal tract and
ponto-/olivo-cerebellar fibers were the major pathways showing strong DAO activity.
In the human corticospinal tract, activity-based staining of DAO did not merge with a
motoneuronal marker, but colocalized mostly with excitatory amino acid transporter 2
and in part with GFAP, suggesting that DAO activity-positive cells are astrocytes seen
mainly in the motor pathway. These findings establish the distribution of DAO activity in
cerebral white matter and the motor system in humans, providing evidence to support the
involvement of DAO in schizophrenia and ALS. Our results raise further questions about
the regulation of D-serine in DAO-rich regions as well as the physiological/pathological
roles of DAO in white matter astrocytes.
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INTRODUCTION
D-Amino acid oxidase (DAO) is an FAD-dependent enzyme
that catalyzes the oxidative deamination of D-isomers of neu-
tral and polar amino acids. Among substrates of mammalian
DAO, D-serine is by far the most abundant in the mammalian
brain and is therefore regarded as its major substrate. In fact,
the D-serine level is inversely related to DAO activity in rodent
brain (Morikawa et al., 2001; Wang and Zhu, 2003; Miyoshi
et al., 2009). Since D-serine is an endogenous coagonist of
N-methyl-D-aspartate (NMDA) glutamate receptors located at
the synapse (Mothet et al., 2000; Panatier et al., 2006; Basu et al.,
2009; Papouin et al., 2012), and also serves as an endogenous lig-
and at the δ2 glutamate receptor (Kakegawa et al., 2011), DAO has
the potential to modulate neurotransmission through D-serine.
D-Serine is converted from L-serine by a PLP-dependent
enzyme, serine racemase (SR) (Wolosker et al., 1999), which is
highly expressed in the brains of mammals including humans
(Verrall et al., 2007; Balu et al., 2014). Due to forebrain-shifted
expression of SR (Miya et al., 2008), D-serine exists in the cere-
bral cortex at approximately 100–150 nmol/g tissue in humans
(Kumashiro et al., 1995; Hamase et al., 2005; Bendikov et al.,
2007), and at 300–350 nmol/g tissue in rodents (Hashimoto et al.,
1993; Nagata et al., 1994; Morikawa et al., 2001) in most studies.
In contrast, abundant DAO in the hindbrain and spinal cord is
believed to keep D-serine at a low level in the regions; the cerebel-
lum of humans (Kumashiro et al., 1995) and rodents (Hashimoto
et al., 1993; Nagata et al., 1994; Morikawa et al., 2001; Wang
and Zhu, 2003) contains D-serine at less than 30 nmol/g tis-
sue, although the results vary in each study depending on the
sensitivity of the method used to determine small amounts of
D-serine.
Based upon activity assays, rodent DAO has been viewed as
an enzyme expressed in the hindbrain and spinal cord (Neims
et al., 1966; Arnold et al., 1979; Horiike et al., 1994). Its activ-
ity has also been detected in the forebrain in some studies,
albeit at only a small fraction of that seen in cerebellum (Neims
et al., 1966; Weimar and Neims, 1977; Madeira et al., 2008). This
view is consistent with the evidence that D-serine is unchanged
or only minimally increased in the cerebral cortex, in contrast
to its marked increase in the cerebellum in mice lacking DAO
activity due to a mutation of G181R (Hashimoto et al., 1993;
Morikawa et al., 2001; Miyoshi et al., 2009). On the other hand,
Frontiers in Synaptic Neuroscience www.frontiersin.org June 2014 | Volume 6 | Article 14 | 1
SYNAPTIC NEUROSCIENCE
Sasabe et al. DAO in human CNS
the distribution of human DAO based on its activity remains
unknown. In contrast to rodents, human DAO may also exist,
to some extent, in the forebrain region. Several lines of evi-
dence support this possibility. First, DAO immunoreactivity has
been detected in the homogenates of human cerebral cortex
(Bendikov et al., 2007; Sacchi et al., 2008); second, the human
cerebral cortex contains only one-third of the D-serine level
found in the corresponding part of the mouse brain. Most
importantly, DAO shows genetic associations with human neu-
rological diseases such as schizophrenia (Chumakov et al., 2002;
Schumacher et al., 2004) and amyotrophic lateral sclerosis (ALS)
(Mitchell et al., 2010), both of which essentially involve forebrain
pathology.
ALS is an adult-onset neurodegenerative disorder charac-
terized by selective loss of upper and lower motor neurons.
Glutamate excitotoxicity is implicated in its pathogenesis (Bruijn
et al., 2004; Van Den Bosch et al., 2006), and the accumu-
lation of D-serine due to reduced activity of DAO possibly
exacerbates hyperactivity of motor neurons via NMDA recep-
tors (Sasabe et al., 2007, 2012; Paul et al., 2014). On the other
hand, schizophrenia is a severely debilitating psychiatric con-
dition, characterized by psychotic features, negative symptoms,
and cognitive defects. A model featuring glutamatergic hypo-
function with accompanying disinhibition of the dopaminergic
system has gained significant support (Carlsson and Carlsson,
1990; Lisman et al., 2008), and reduced D-serine due to activa-
tion of DAO triggered hypofunction of NMDA receptors may
be partly responsible (Kapoor et al., 2006; Burnet et al., 2008;
Madeira et al., 2008; Labrie et al., 2012; Van Horn et al., 2013). In
the present study, we used post-mortem brains with intact DAO
enzymatic activity and demonstrated the distribution of DAO
using an activity-based staining method, with a major focus on
differences between humans and mice in the forebrain region and
motor pathways.
MATERIALS AND METHODS
HUMAN SAMPLES
Postmortem specimens were collected from cadavers donated
after death with prior consent at Keio University School of
Medicine. A male cadaver who had died of gastric cancer at 89 y/o
was examined at 13 h postmortem, a male cadaver who had died
of gastrointestinal hemorrhage at 86 y/o was at 28 h, and a female
cadaver who had died of bile duct cancer at 92 y/o was at 36 h.
All of them were Japanese. Neuropathological assessment of their
brain did not identify any metastasis of cancer or neurodegen-
erative abnormalities other than minor age-related changes. The
specimens were dissected after perfusion from the thoracic aorta
with ice-cold phosphate buffer-saline (PBS, pH 7.4). The pieces of
brain tissue were processed individually for enzyme activity assay
or histological analysis.
ANIMALS
All experiments on animals were carried out in accordance
with institutional guidelines. The study protocol was approved
by the Animal Experiment Committee of Keio University.
C57BL/6J mice were obtained from CLEA Japan (Tokyo,
Japan).
ENZYME ACTIVITY ASSAY OF DAO
The dissected pieces of human tissue for enzyme activity assay
were kept at −80◦C without fixation until use. C57BL/6J male
mice at 8 weeks of age were euthanized and maintained at 4◦C.
Mouse tissue was collected at 0, 12, 24, or 48 h after death
and kept at −80◦C until use. Tissue was homogenized in 7mM
sodium pyrophosphate (pH 8.3) at 3500 rpm for 2min using
Micro Smash MS-100 (Tomy, Tokyo, Japan) and centrifuged at
5500 × g for 10min. The activity of DAO was determined as
described previously (Sasabe et al., 2012, 2014). Briefly, 50μl
tissue lysate was added to a mixture [150μl of 100mM D-Ala,
100μl of 0.1mM flavin adenine dinucleotide (FAD), 150μl of
700 units/ml catalase in 133mM sodium pyrophosphate (pH 8.3),
and 50μl of 70% v/v MeOH], processed with constant agita-
tion at 37◦C for 30–60min, and terminated by adding 500μl of
10% trichloroacetic acid. To 250μl of the supernatant solution
were added 250μl of 5M KOH and 250μl of 0.5% 4-amino-3-
hydrazino-5-mercapto-1,2,4-triazole in 0.5M HCl. After 15min
incubation at room temperature, 250μl of 0.75% KIO4 in 0.2M
KOH was added to the mixture with vigorous shaking, and
absorbance at 550 nm was measured. DAO activity was calcu-
lated as described by Watanabe et al. (1978) and expressed as
the amount of D-alanine oxidized per minute per milligram of
protein.
HISTOLOGICAL ANALYSIS
The human tissue pieces for enzyme histochemistry were fixed
in 2% paraformaldehyde in PBS on ice for 2 h. Mice were anes-
thetized with diethyl ether and perfused transcardially with ice-
cold PBS and subsequently with 2% paraformaldehyde in PBS.
Human and mouse tissues were then cryoprotected in a 20%
sucrose solution in PBS at 4◦C overnight. They were frozen
in Tissue-Tek O.C.T. Compound (Sakura Finetek Japan, Tokyo,
Japan). Sections 15μm thick were sliced on a cryostat at −19◦C
and stored at −80◦C until they were used.
For double staining, the procedure for immunofluores-
cence was done prior to that of the enzyme histochemistry.
Sections were rinsed in PBS and incubated in a blocking
solution containing appropriate normal serum (1:60; Vector
Laboratories, Cambridgeshire, UK) at room temperature for 1 h.
Subsequently, they were incubated in appropriate primary anti-
bodies [non-phosphorylated neurofilament H (npNFH), SMI32
(1:100; Covance, Princeton, NJ, USA); glial fibrillary acidic pro-
tein (GFAP) (1:300; Dako, Glostrup, Denmark); and excitatory
amino acid transporter 2 (EAAT2/GLT-1), AB1783 (1:100; Merck
Millipore, Darmstadt, Germany)] diluted in PBS containing
blocking serum at 4◦C overnight, rinsed in PBS, and trans-
ferred into species-specific secondary antibodies conjugated with
Texas-Red (1:250, Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) at room temperature for 40min. The sections
were then rinsed again in PBS and incubated in a DAO-activity
staining solution [7mM pyrophosphate buffer (pH 8.3), 0.1%
horseradish peroxidase (Sigma-Aldrich, St. Louis, MO, USA),
FITC-conjugated tyramide (1:400; Perkin-Elmer, Waltham, MA,
USA), 0.065% sodium azide, 0.6% nickel ammonium sulfate,
22mM D-proline, 20μM FAD] (Sasabe et al., 2012) at room
temperature for 10min in the dark. They were washed in PBS
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and mounted using ProLong Gold Antifade Reagent (Invitrogen,
Carlsbad, CA, USA).
Sections were imaged using a BZ-9000 fluorescent micro-
scope (Keyence, Osaka, Japan) for joint images and a Zeiss LSM
510 confocal microscope (Carl Zeiss, Oberkochen, Germany) for
double-stained images.
All images in the figures are from the 89 y/o male. The results
of DAO-enzyme histochemistry in Figure 2 were also confirmed
in the sections from the 92 y/o female.
STATISTICS
All values in the figures of this study indicate means ± standard
error of mean (SEM). Statistical analyses for the experiments were
performed with one-way ANOVA followed by Tukey’s multiple
comparison test, in which P < 0.05 was assessed as significant.
All analyses were performed using Prism 5 (GraphPad Software,
La Jolla, CA, USA). A sample size of 3 in each group has an 80%
power to detect a difference between means of 8.73 (estimated
SD = 3.0) with a significance level of 0.05, which was calculated
using StatMate (GraphPad Software).
RESULTS
TISSUE DAO ACTIVITY IN HUMAN AND MOUSE CENTRAL NERVOUS
SYSTEMS
DAO activity is restricted to hindbrain and spinal cord in rodents
and is strongest in their cerebella (Horiike et al., 1994). To deter-
mine DAO activity in human tissue, we obtained a variety of
CNS specimens at autopsy gifted from three individuals. In mice,
DAO activity did not wane over time until 48 h after death
(Figure 1), validating the freshness of the human specimens for
DAO activity assay. DAO activity was detected in all the human
specimens examined (Figure 1). Surprisingly, the human cerebral
cortices of Brodmann area 1–3 (primary somatosensory cortex,
PSC) and area 4 (primary motor cortex, PMC) and the inter-
nal capsule showed mild DAO activity, while in mice there was
no such activity in the cerebral cortex or the striatum, includ-
ing the internal capsule [Figure 1A, F(5, 12) = 6.071, P = 0.0050;
human PSC, 1.60 ± 0.44; human PMC, 1.95 ± 0.81; mouse 0 h,
N.D.; mouse 12 h, N.D.; mouse 24 h, N.D.; mouse 48 h, N.D.]
[Figure 1B, F(4, 10) = 25.55, P < 0.0001; human, 2.17 ± 0.43;
mouse 0 h, N.D.; mouse 12 h, N.D.; mouse 24 h, N.D.; mouse
48 h, N.D.] (unit: nmol/minmg protein). Activity in the basi-
lar part of pons and thoracic spinal cord was comparable to
that in the cerebellar cortex in humans, whereas it was one-
tenth of that in the cerebellum in mice [Figure 1C, F(4, 10) =
67.26, P < 0.0001; human, 23.62 ± 2.50; mouse 0 h, 2.63 ± 0.09;
mouse 12 h, 2.73 ± 0.28; mouse 24 h, 2.84 ± 0.37; mouse
48 h, 2.83 ± 0.27] [Figure 1D, F(4, 10) = 53.14, P < 0.0001;
human, 34.84 ± 1.03; mouse 0 h, 20.04 ± 0.46; mouse 12 h,
20.36 ± 0.32; mouse 24 h, 20.90 ± 1.48; mouse 48 h, 18.63 ±
0.81] [Figure 1E, F(4, 9) = 8.467, P = 0.0041; human, 22.65 ±
8.89; mouse 0 h, 4.23 ± 0.12; mouse 12 h, 3.76 ± 0.14; mouse
24 h, 3.89 ± 0.23; mouse 48 h, 3.86 ± 0.42] (unit: nmol/minmg
protein). These results delineated the difference of DAO distri-
bution in the central nervous system (CNS) between humans
and mice.
FIGURE 1 | Quantitative DAO activity in human and mouse tissue. Tissue
DAO activities in human and mouse CNS were measured. Mouse tissues
were dissected at indicated hours after the death. (A) PSC and PMC of
human cerebral cortex (n = 3, each), and whole mouse cerebral cortex
(n = 3, each). (B) Posterior limb of human internal capsule (n = 3) and mouse
striatum (n = 3, each). (C) Ventral part of human pons (n = 3) and mouse
brainstem (n = 3, each). (D) Posterior lobe in hemisphere of human
cerebellum (n = 3) and whole mouse cerebellum (n = 3, each). (E) Thoracic
parts of human spinal cord (n = 2, we could not obtain the spinal cord from
86 y/o male) and of mouse spinal cord (n = 3, each). N.D. is “not detected.”
N.S. means “not significant.” ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 (One-Way
ANOVA followed by Tukey’s multiple comparison test, N.S. and asterisks in
the figures are comparison to “mouse 0 h”). Data are plotted as the
mean ± s.e.m.
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REGIONAL ACTIVITY OF DAO IN HUMAN AND MOUSE BRAINS
Next, we compared the tissue distribution pattern of DAO activity
between humans andmice in various regions of brain using a sen-
sitive technique for enzyme histochemistry (Sasabe et al., 2012).
This technique is based on covalent binding of fluorescence-
conjugated tyramide catalyzed by horseradish peroxidase in the
presence of hydrogen peroxide, produced by degradation of exter-
nally added D-proline mediated by endogenous DAO. The speci-
ficity of this technique to DAO activity was shown in our previous
study by using L- instead of D-proline as a substrate of DAO
or using sections from mice lacking DAO activity (Sasabe et al.,
2012). Its specificity to DAO activity was also tested on human
sections; we did not observe any signals when we used L-proline
as a substrate (Supplementary Figure 1). We stained sections
from two individuals, and staining images from both showed
comparable pattern.
Cerebral cortex and hippocampus
DAO activity was found predominantly in the subcortical
white matter of Brodmann areas 1–3 (PSC), area 4 (PMC),
and area 9 (dorsolateral prefrontal cortex, DPFC) in humans
(Figures 2A–C). In the human hippocampus, enzyme reactivity
was absent in the pyramidal cell layer of CA1–4 and in the granule
cell layer of dentate gyrus (DG), whereas it was slightly detected
in the molecular layer and clearly in the fimbria, a band of white
matter (Figure 2D). On the other hand, in mice, DAO activity
was not observed in either white or gray matter of the cerebral
cortex, or in the hippocampus, except slightly in the fimbria (fi)
of hippocampus (Hip) (Figure 2E).
Internal capsule
The internal capsule consists of three parts: the anterior limb,
the posterior limb, and the genu. Within the posterior limb are
descending fibers that include corticospinal, corticorubral, and
corticoreticular tracts as well as ascending sensory fibers from the
thalamus to the cerebral cortex. DAO enzyme activity was visible
in the posterior limb of internal capsule (PLIC) as well as in the
globus pallidus (GP) and ventral lateral part of thalamus (VLTh)
in the human brain (Figure 2F), whereas it was undetectable in
the corresponding regions in mice (Figure 2G).
Cerebellum
DAO activity was localized predominantly to the cortex in the
cerebellar hemisphere of both humans and mice (Figures 2H,I).
The activity was strongest in the molecular layer (Mol), patchy in
the granular layer (Gr), and mild in the white matter (WM).
Mesencephalon
DAO activity was seen throughout the mesencephalon in humans
(Figure 2J), while it was restricted to the ventral side in mice
(Figure 2K). In humans, DAO activity was strong in sub-
stantia nigra (SN), cerebral peduncle (CP), and oculomotor
nucleus (OcuNu); moderate in ventral and dorsal trigeminal
tracts (VTT and DTT), spinothalamic tract (SThT), and medial
longitudinal fasciculus (MLF); mild in ventral tegmental area
(VTA) and reticular formation (RF); and slight in red nucleus
(RNu), medial lemniscus (ML), and superior colliculus (SC)
(Figure 2J). In mice, DAO activity was detectable in VTA, mildly
in ML, RNu, and CP, and was absent, in clear contrast with
humans, in SN as well as in SC and periaqueductal gray (PAG)
(Figure 2K).
Pons
In humans, the basilar portion of the pons is well developed and
includes tracts that conduct signals from the cerebrum down to
the cerebellum and medulla, as well as tracts that carry sensory
signals up into the thalamus. DAO activity was detected through-
out the basilar part, with intensities descending in the following
sequence: pontine nucleus (PNu), CP, and pontocerebellar fibers
(PCfi). In the tegmentum of the human pons, DAO activity was
observed strongly in VTT and anterolateral system (AnLS), mildly
in RF, and marginally in ML (Figure 2L). On the other hand, in
mice, RF occupies most of the pons. DAO activity was widely seen
in RF, ML, and dorsal raphe nucleus (DRNu), whereas it was mild
in lateral lemniscus (LL) and almost absent in MLF and CP in
mice (Figure 2M).
Medulla oblongata
The medulla oblongata is structurally a site of transition between
the midbrain and spinal cord, with the white matter on the
outside and the gray matter on the inside. It not only relays
motor and sensory fibers but also contains the nuclei of sev-
eral cranial nerves. In the white matter of human medulla, DAO
activity was highly observed in AnLS, anterior spinocerebel-
lar tract (ASCT), pyramid (Py), and rubrospinal tract (RuST),
while it was marginal in ML, tectospinal tract (TT), MLF, spinal
trigeminal tract (STT), and restiform body (RB) (Figure 2N).
In contrast, DAO activity was a trace in mouse Py (Figure 2O).
In the gray matter of human medulla, olivary nucleus (OlNu),
solitary nucleus (Sol), and spinal trigeminal nucleus (STNu) had
moderate DAO activity; and hypoglossal nucleus (HyNu), medial
vestibular nucleus (MVNu), inferior vestibular nucleus (IVNu),
ambiguus nucleus (AmNu), and aucuate nucleus (ArNu) showed
relatively weak activity (Figure 2N). The distribution of DAO
in HyNu, STNu, Sol, AmNu, and inferior olive (IO) in mice
appeared to be similar to that in humans (Figure 2O). DAO activ-
ity was undetectable in cuneate nucleus (Cu) and gracile nucleus
(Gr) in mice (Figure 2O). RF, which is classified as neither white
or gray matter, comprises a large portion of the medulla, and was
rich in DAO activity in both humans and mice (Figures 2N,O).
Spinal cord
In spinal cord, DAO activity was seen in both white and gray mat-
ters. In humans, the activity in the white matter was stronger
than that in the gray matter, while the activity in the gray
matter was dominant in mice. Among descending pathways in
the white matter of humans, we detected potent DAO activ-
ity in pyramidal tracts that consist of lateral corticospinal tract
(LCST) and anterior corticospinal tract (ACST); moderate in
extrapyramidal tracts, such as RuST, medullary reticulospinal
tract (MReST), and pontine reticulospinal tract (PReST); and
slight in vestibulospinal tract (VST) (Figure 2P). On the other
hand, ascending pathways of humans showed DAO activity in the
following sequence: AnLS, ASCT, posterior spinocerebellar tract
(PSCT), gracile fasciculus (GrF), and cuneate fasciculus (CuF)
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FIGURE 2 | DAO enzyme histochemistry in human and mouse CNS. DAO
activity was visualized using D-proline as a substrate in various regions of
brain. Shown are (A–C) human cerebral cortex, (D) human hippocampus, (E)
mouse forebrain including cerebral cortex and hippocampus (a coronal
section), (F) posterior limb of human internal capsule (a horizontal section),
(G) mouse striatum and internal capsule (a coronal section), (H) posterior
lobe in human cerebellar hemisphere, (I) mouse cerebellar hemisphere, (J)
human mesencephalon, (K) mouse mesencephalon, (L) basilar part of human
pons, (M) mouse pons, (N) human medulla oblongata, (O) mouse medulla
oblongata, (P) human thoracic spinal cord, and (Q) mouse thoracic spinal
cord. (J–Q) Upper sides of the images are dorsal; bottom sides are ventral.
(B,F,J,L,N,P) Arrows indicate the corticospinal tract. Each image of humans
was low magnified to compare them to the corresponding image of mice,
and the magnification percentage is different in each image.
(Figure 2P). In mice, neither ascending nor descending path-
ways are fully understood. DAO activity was strongly observed in
ventral funiculus (VF), whereas it was detected weakly in dorsal
corticospinal tract (DCS) and lateral funiculus (LF), and was
almost absent in RuST, GrF, and CuF in mice (Figure 2Q). In the
gray matter of humans and mice, the DAO activity in the ventral
horn (VH) was relatively lower than that in the dorsal horn (DH)
(Figures 2P,Q).
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CELLULAR DISTRIBUTION OF DAO ACTIVITY IN HUMAN
CORTICOSPINAL TRACT
We found DAO activity along with motor axons throughout
the corticospinal tract in humans (Figures 2B,F,J,L,N,P). In the
PMC, DAO activity was absent in or around motor neurons,
stained with npNFH, of the gray matter (Figure 3A), whereas the
activity in the white matter was detected in GFAP-positive astro-
cytes in part (Figure 3B). In a similar fashion, in the spinal cord,
DAO activity was not detectable in the cell bodies of npNFH-
positive neurons of Lamina IX in the gray matter (Figure 3C).
DAO activity in the spinal LCST existed around motor axons and
myelin sheath (Figure 3D) and colocalized with GFAP-positive
astrocytes (Figure 3E).
DAO is thought to regulate NMDA glutamate receptors
through degrading D-serine. To find out whether DAO can
contribute locationally to the D-serine level in glutamatergic
synapses, DAOwas co-stained with an astrocytic glutamate trans-
porter EAAT2, which comprises 95% of the total glutamate
uptake in the CNS (Tanaka et al., 1997; Williams et al., 2005).
DAO-activity staining overlapped about half of the EAAT2-
positive dots on the morphologically identified motor neurons
in Lamina IX of the human spinal VH (Figure 4A). Not located
merely on the surface of the neurons, DAO activity was merged
with EAAT2-positive astrocytes for the most part in the spinal
VH (Figure 4A), the spinal LCST (Figure 4B), and the white
matter of PMC (Figure 4C). These colocalizations suggested the
inseparable relationship between the regulations of glutamate
and D-serine in controlling the activity of NMDA glutamate
receptors.
DISCUSSION
We have shown the distribution of DAO based on its enzymatic
activity in human andmouse CNS. In the forebrain, DAO activity
is distributed to the cerebral white matter and internal capsule
along with the ascending and descending nerve fibers in humans,
while it is undetectable in mice. DAO activity is detected in the
midbrain, hindbrain, and spinal cord in both humans and mice.
The activity is prominent along the corticospinal and rubrospinal
tracts, anterolateral and nigrostriatal systems, and ponto-/olivo-
cerebellar fibers in humans. In mice, the corticospinal and
rubrospinal tracts and nigrostriatal system show minimal DAO
activity, whereas strong activity is detectable in the reticulospinal
tract and ponto-/olivo-cerebellar fibers (Table 1). In the human
corticospinal tract, DAO-activity staining colocalizes mostly with
EAAT2- and partly with GFAP-positive cells.
There are complexities and controversies regarding the local-
ization of DAO in rodent brain, in terms of both region and
cell type, due to differences between activity and expression.
The activity-based staining, using DAO enzyme histochemistry,
consistently shows that rodent DAO is a glial enzyme exclu-
sively found in hindbrain and spinal cord (Arnold et al., 1979;
Horiike et al., 1994; Sasabe et al., 2012). On the other hand,
DAO immunoreactivity is also detectable in frontal cortex and
hippocampus although the cerebellum and brainstem are gener-
ally more immunoreactive than the forebrain regions (Moreno
et al., 1999). A possible explanation for the different results
obtained using different methodologies is that DAO protein can
be detected by immunohistochemistry even if it is not active.
Such a difference exists also in humans. Human DAO activ-
ity can be detected only in the white matter in the forebrain
region (Figures 2A–D), whereas immunoreactivity is observable
in both cerebral gray and white matters (Verrall et al., 2007).
Although DAO immunoreactivity is detectable in both neurons
and astrocytes in the cerebral gray matter (Verrall et al., 2007;
Sacchi et al., 2008), DAO is inactive in all cell types in the region
(Figure 2A). Active DAO can be seen in non-neuronal cells in
FIGURE 3 | Cellular distribution of DAO enzymatic activity in human
corticospinal tract. DAO enzyme histochemistry in the gray (A) or
white (B) matter of PMC, thoracic spinal VH (C), or LCST (D,E) in
humans was double stained with npNFH, a marker for motor neurons,
or GFAP, an astrocytic marker. (C–E) The lower right panel is higher
magnification of a white square in the lower left. The arrowheads point
to blanks indicating the myelin sheath. The asterisk shows blood
vessel. Scale bars, 200μm.
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FIGURE 4 | Colocalization of DAO enzymatic activity and EAAT2. DAO
enzyme histochemistry was performed after immunohistochemistry of EAAT2
in human thoracic spinal VH (A), spinal LCST (B), and white matter of PMC
(C). The lower right image is an enlargement of the white square in the lower
left image. Arrowheads show dots on the surface of a motor neuron with both
DAO and EAAT2. The asterisk indicates blood vessel. Scale bars, 200μm.
Table 1 | DAO activity in major neural pathways.
Human Mouse
DESCENDING PATHWAYS
Corticospinal tracts ++ ±
Reticulospinal tracts + ++
Rubrospinal tracts ++ ±
Vestibulospinal tracts ± −
Tectospinal tracts ± +
ASCENDING PATHWAYS
Posterior column-ML ± ±
Anterolateral system ++ NS
Trigeminal pathways ± ±
Solitary pathways + +
Spinocerebellar tracts + NS
Ponto-/olivo-cerebellar fibers ++ ++
Nigrostriatal system ++ −
Enzyme activity: −, absent; ±, weak; +, moderate; ++, strong; NS, not
specified.
the white matter throughout the corticospinal tract and in the
spinal gray matter (Figures 3, 4). Some non-neuronal cells with
DAO activity are GFAP-negative, but most of them are EAAT2-
positive (Figures 3, 4). Although GFAP in the CNS is exclusively
expressed by astrocytes, up to 85% of astrocytic processes do
not contain GFAP (Ludwin et al., 1976; Bushong et al., 2002).
Also, susceptibility to degradation may affect the antigenicity of
GFAP (DeArmond et al., 1983). Not only duration after the death,
but also weak fixation of tissue for DAO-enzyme histochemistry
could interfere the stability of GFAP in the process of histolog-
ical analysis of human tissue. To keep DAO activity for enzyme
histochemistry, we minimized fixation of tissue. But, at the same
time, the weak fixation is a risk of protein degradation and loss
of structural stability may result in poor labeling of GFAP by
immunohistochemistry. Our results in Figures 3, 4 might just
indicate that EAAT2 has better antigenicity than GFAP in the
weakly fixed tissue. In either case, considering that astrocytes
express high levels of EAAT2 (Lee and Pow, 2010), the DAO-
positive non-neuronal cells are mostly astrocytes in the human
corticospinal tract and spinal gray matter. Since the D-serine level
has a clear inverse relation to DAO activity, astrocytic DAO is
deemed to have a certain role in D-serine regulation in the human
motor pathway.
What is the physiological significance of astrocytic DAO? It
remains unclear how D-serine is regulated in DAO-rich CNS
regions. Knockout studies show that D-serine is produced by its
synthetic enzyme SR primarily in neurons (Miya et al., 2008; Balu
et al., 2014), but it is controversial which cell types play roles
in D-serine storage, release into extracellular space, and removal
from it. In his seminal reviews, Wolosker explains the kinetics of
serine enantiomers, called a “serine-shuttle” model, in the cere-
bral gray matter where DAO is basically inactive (Wolosker, 2011;
Wolosker and Radzishevsky, 2013): D-serine is converted in neu-
rons from L-serine provided by astrocytes; is released predomi-
nantly by neurons; is uptaken and stored in vesicles in astrocytes
(Martineau et al., 2013); and is degraded by SR through its α,
β-elimination activity in neurons. Because mice lacking DAO
activity show a striking increase in D-serine in DAO-rich regions
(Hashimoto et al., 1993; Morikawa et al., 2001; Miyoshi et al.,
2009), not only SR but also DAO seems to be essential for D-serine
regulation in these regions. Given that D-serine is synthesized in
neurons also in DAO-rich regions, such as cerebellar or spinal
gray matter, D-serine should be transported actively to astro-
cytes and degraded by astrocytic DAO in the gray matter. Thus,
DAO may influence physiological NMDA receptor functions by
modulating D-serine availability in the synapse. Furthermore,
apart from NMDA receptor modulation, DAO may also influ-
ence δ2 glutamate receptor function, which D-serine binds to as
an endogenous ligand, in cerebellar gray matter (Kakegawa et al.,
2011).
On the other hand, the role of astrocytic DAO in the white
matter is enigmatic. Astrocytes in the white matter, called fibrous
astrocytes, have small cell bodies, and their processes align with
myelinated fibers, facilitating myelination in the CNS. Since glu-
tamate overload causes excitotoxicity via ionotropic glutamate
receptors, such as NMDA receptors, not only on neuronal cell
bodies or axons but also on oligodendrocytes (Oka et al., 1993;
Borges et al., 1994; Karadottir et al., 2005), effective clearance
of glutamate and D-serine might be required also in the white
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matter. In support of this view, the glutamate concentration in the
white matter is only half of what is found in the graymatter in vivo
(Hassel et al., 2003); the level of glutamate transporters is high-
est in astrocytes isolated from the white matter, and capacity for
metabolism of glutamate to glutamine is higher in white matter
astrocytes than in gray matter astrocytes in vitro (Goursaud et al.,
2009). Because D-serine but not glycine is the dominant coagonist
for NMDA receptor-mediated neurotoxicity (Shleper et al., 2005)
and glycine but not D-serine is the major coagonist of “extrasy-
naptic” NMDA receptors (Papouin et al., 2012), degradation of
D-serine by astrocytic DAO in the white matter might be neces-
sary tomaintaining healthy axons. Furthermore, D-serine triggers
excitatory responses in CNS myelin through NR1/NR3 NMDA
receptor (Pina-Crespo et al., 2010), suggesting that regulation of
D-serine by white matter astrocytes may also affect physiology
of oligodendrocytes. Considering that the distribution of human
DAO activity is more widespread and prominent in the white than
in the gray matter (Figure 2), in future studies, the physiologi-
cal roles of DAO should be clarified in terms of modulation of
extrasynaptic NMDA receptors on neurons and myelination or
nerve conduction by oligodendrocytes.
Human DAO distribution in cerebral subcortical white matter
and internal capsule (Figures 2A–C) implies widespread distri-
bution along with fibers that connect between cerebral neocortex
and lower brain. In contrast, in mice, such connection is much
less developed and DAO activity is confined to the lower brain,
suggesting that D-serine regulation through DAO is related to
modulate neural network in the primitive part of brain. Since
cerebral cortex has highly evolved to control the lower brain in
humans, sophisticated connections are required between the two
areas of brain. Considering that one of such connections, the cor-
ticospinal tract, originates not only from motor cortex but also
from sensory and prefrontal cortices, distribution of DAO activ-
ity found in human subcortical white matters of these regions of
cortices may imply that DAO-positive cells may have penetrated
into cerebral cortex along with the evolution of human brain.
The neural pathways that show potent DAO activity imply
a strong physiological association of D-serine regulation in the
motor system, which consists of the pyramidal and extrapyra-
midal systems. The pyramidal system is also called the corti-
cospinal tract, while the extrapyramidal system includes several
neural pathways, such as the rubrospinal, reticulospinal, vestibu-
lospinal, and tectospinal tracts. The extrapyramidal system is
modulated by various parts of the CNS, including the nigros-
triatal system, cerebellum, and cerebral sensory cortex. DAO
activity is detectable in most of the pyramidal and extrapyramidal
systems in humans, whereas it is observed mainly in the reticu-
lospinal tract and cerebellar fibers in mice (Figure 2 and Table 1).
Although in humans, the pyramidal system that connects cerebral
motor cortex to spinal motor neurons is especially well devel-
oped (Lawrence and Kuypers, 1968; Lemon, 2008), there are
no direct connections in rodents. Considering that in rodents,
the reticulospinal tract primarily relays cortical input to spinal
motor neurons (Yang and Lemon, 2003; Alstermark et al., 2004),
such distributional differences of DAO between humans andmice
might result from an evolutionary shift in the region responsi-
ble for voluntary movement. These differences may explain the
paradox that DAO is inactivated in the reticulospinal but not
the pyramidal tract in a mouse model of ALS (Sasabe et al.,
2012) although in human, ALS primarily involves pathology of
the pyramidal tract.
Strong DAO activity is detectable in human nigrostriatal sys-
tem too, suggesting that DAO may affect not only glutamatergic
but also dopaminergic neurons. Since D-DOPA is unidirection-
ally converted to L-DOPA mediated by DAO (Wu et al., 2006),
the substrate of DAO in the nigrostriatal system might not be
D-serine but DOPA, a precursor of dopamine, norepinephrine,
and epinephrine. Given that DAO is overactivated in schizophre-
nia (Verrall et al., 2010), D-serine and dopamine beingmodulated
by DAO may constitute a new aspect of a model of aberrant
glutamatergic and dopaminergic neurons in schizophrenia.
Thus, we surveyed the regional distribution of human DAO
activity in comparison to mouse DAO, which has led to a novel
understanding of physiological and pathological roles of DAO in
the human CNS. The cellular distribution and its specific role in
each neural pathway remain largely unclear and warrant further
examinations.
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